Clinical Trials on Plasma Caffeine Concentration in United Kingdom

Total 2567 results

Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Rituximab Plus Fludarabine in Treating Patients With Waldenstrom's Macroglobulinemia

Lymphoma

United States, Canada, United Kingdom, Sweden
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

Pain | Urinary Complications | Breast Adenocarcinoma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | Metastatic Malignant Neoplasm to the Bone | Musculoskeletal Complication

United States, Puerto Rico
Janssen-Cilag International NV

Completed

Velcade Consolidation Bone Study

Multiple Myeloma

Turkey, Greece, Czech Republic, Austria, Germany, Sweden, United Kingdom, Denmark
University of Utah

Active, not recruiting

Validation of a Low-cost Platelet-Rich Plasma (PRP) (PRP)

Platelet-Rich Plasma (PRP) | Knee Osteoarthritis (OA)

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer

Lymphoma | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Radiation Toxicity | Oral Complications | Drug/Agent Toxicity by Tissue/Organ

United States
GlaxoSmithKline

Recruiting

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments (DREAMM-20)

Multiple Myeloma

Australia, Poland, Taiwan, Korea, Republic of, Japan, United Kingdom, Brazil, Mexico, Turkey, Argentina
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

Multiple Myeloma | Plasma Cell Neoplasm

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma

Plasma Cell Myeloma | Secondary Amyloidosis

United States
Celgene

Recruiting

An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma (KarMMa-2)

Multiple Myeloma

United States, France, Germany, Spain, United Kingdom, Italy
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

Smoldering Plasma Cell Myeloma

United States
Sanofi

Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma

Plasma Cell Myeloma

United States, Czechia, France
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

A Standardized Nursing Intervention Protocol for HCT Patients

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Psychosocial Effects of Cancer and Its Treatment | Myelodysplastic/Myeloproliferative Neoplasms | Therapy-related Toxicity

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Graft Versus Host Disease

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy

Lymphoma | Leukemia | Anemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma

Monoclonal Gammopathy of Undetermined Significance | Smoldering Plasma Cell Myeloma

United States
Hoffmann-La Roche

Recruiting

A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)

Multiple Myeloma

Belgium, Korea, Republic of, Denmark, United Kingdom, Australia, New Zealand, Italy, Spain, France
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Recurrent Plasma Cell Myeloma | Loss of Chromosome 17p

United States
Sanofi

Recruiting

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

Plasma Cell Myeloma

Czechia, Australia, Chile, France, Spain, United States, Brazil, China, Greece, Japan, Korea, Republic of, Sweden, Taiwan, Finland, Italy, Russian Federation
Stichting European Myeloma Network
Fondazione EMN Italy Onlus

Completed

COVID-19 Infection and Multiple Myeloma (EMN-COVID)

Covid19 | Multiple Myeloma | Corona Virus Infection

Czechia, Netherlands, United Kingdom, Belgium, Germany, Austria, Greece, Italy
Sidney Kimmel Comprehensive Cancer Center at Johns...
Incyte Corporation

Recruiting

Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients

Myelodysplastic Syndromes | Myeloproliferative Disorders | Multiple Myeloma | Plasma Cell Leukemia | CML | T-cell Prolymphocytic Leukemia | Leukemia, Acute | Myelomonocytic Leukemia, Chronic

United States
Case Comprehensive Cancer Center

Completed

Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Terminated

Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease | Lymphoproliferative Disorder | Myelodysplastic/Myeloproliferative Neoplasms

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow Transplantation

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Psychosocial Effects of Cancer and Its Treatment

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Graft Versus Host Disease

United States
Stichting European Myeloma Network
Janssen Pharmaceutica

Recruiting

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4)

Multiple Myeloma

United Kingdom, Czechia, Australia, Austria, Belgium, Denmark, Germany, Greece, Italy, Netherlands, Norway, Serbia, Switzerland, Turkey, Brazil
University of Southern California
National Cancer Institute (NCI)

Recruiting

Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma

Plasma Cell Myeloma | Metastatic Malignant Neoplasm in the Bone | Bone Pain

United States
Case Comprehensive Cancer Center

Completed

Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases

United States
The Cleveland Clinic
National Cancer Institute (NCI)

Completed

Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Psychosocial Effects of Cancer and Its Treatment

United States
Massachusetts General Hospital

Completed

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease | Myelodysplastic/Myeloproliferative Neoplasms

United States
Vanderbilt University
National Cancer Institute (NCI)

Completed

Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Nonmalignant Neoplasm | Lymphoproliferative Disorder | Myelodysplastic/Myeloproliferative Neoplasms | Methemoglobinemia

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Graft Versus Host Disease

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy

Lymphoma | Leukemia | Small Intestine Cancer | Prostate Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders

Sarcoma | Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Graft Versus Host Disease

United States
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Recruiting

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Nonmalignant Neoplasm | Lymphoproliferative Disorder | Myelodysplastic/Myeloproliferative Neoplasms

United States
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer

Lymphoma | Leukemia | Breast Cancer | Ovarian Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm

United States
Hoag Memorial Hospital Presbyterian
Cancer Biotherapy Research Group

Completed

Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous/Nonmalignant Condition

United States
University of Michigan Rogel Cancer Center

Completed

Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood

Myelodysplastic Syndromes | Myeloproliferative Disorders | Lymphoma, Malignant | Waldenstrom's Macroglobulinemia | Myeloma, Plasma-Cell

United States
Sanofi

Completed

Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Plasma Cell Myeloma

France, Italy, Czechia, Greece, Spain, Canada, Australia, United States, Brazil, Hungary
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Nonmalignant Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Terminated

Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation

Multiple Myeloma and Plasma Cell Neoplasm | Drug/Agent Toxicity by Tissue/Organ

United States
Merz Aesthetics GmbH

Completed

A Study of NT 201 Doses in the Treatment of Platysma Prominence (PAOLA)

Platysma Prominence

United States
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Relapsed or Refractory Multiple Myeloma | Previously Treated Amyloid Light-chain (AL) Amyloidosis

Belgium, United States, United Kingdom, Spain, France, Netherlands
Prothena Biosciences Ltd.

Terminated

Study in Subjects With Light Chain (AL) Amyloidosis

AL Amyloidosis

United States, Spain, Australia, Italy, Germany, Austria, Greece, France, Israel, United Kingdom
Sanofi

Active, not recruiting

A Phase 3 Randomized, Open-label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With High-risk Smoldering Multiple Myeloma

Plasma Cell Myeloma

Italy, Korea, Republic of, Norway, Canada, Spain, Germany, Greece, Lithuania, Sweden, Israel, Hungary, France, Japan, Australia, China, Denmark, Czechia, Turkey, United States, Brazil, Ireland, New Zealand, Poland, United Kingdom
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Completed

A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

United States, Philippines, United Kingdom
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI)

Terminated

12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Precancerous/Nonmalignant Condition

United States
ConBio, a Cynosure Company

Completed

Study of Laser Treatment of Melasma

Refractory Mixed Type Melasma

United States
University of Nebraska
National Cancer Institute (NCI)

Completed

Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Graft Versus Host Disease | Secondary Myelofibrosis

United States

Clinical Trials on Plasma Caffeine Concentration in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations